OwlTail

Cover image of Toni K. Choueiri

Toni K. Choueiri

9 Podcast Episodes

Latest 28 Aug 2021 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel therapies. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 33mins

12 Jul 2021

Episode artwork

Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel therapies. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 33mins

12 Jul 2021

Similar People

Episode artwork

Toni K. Choueiri, MD - Rethinking the Care of Renal Cell Carcinoma: Expert Perspectives on Novel Agents, Combinations, and Sequencing Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/GHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In a new CME- and ABIM MOC-certified program on RCC from PeerView and the Kidney Cancer Research Alliance (KCCure), an expert faculty panel will share how to optimally select and sequence treatment regimens across multiple lines of therapy for patients with advanced RCC, talk about new options for resectable RCC, and discuss clinical trials involving novel therapies. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targeted TKIs, immuno-oncology (IO) agents, and novel combination approaches, for advanced renal cell carcinoma (RCC), Integrate recent clinical research findings on validated TKI and IO-based options into the development of individualized treatment plans for patients with newly diagnosed and previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for RCC patients in different disease and treatment settings, Implement practical strategies to mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 33mins

12 Jul 2021

Episode artwork

Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 16mins

21 Apr 2021

Most Popular

Episode artwork

Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 16mins

21 Apr 2021

Episode artwork

Toni K. Choueiri, MD - RCC MasterClass and Clinical Consult: Remodeling the Treatment Algorithm With Novel Immune and Targeted Therapies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/QEY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of renal cell carcinoma (RCC) continues to expand rapidly with the addition of novel multi-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations, has increased the number of treatment choices in the frontline setting of advanced RCC. Oncologists and other healthcare professionals who manage patients with RCC are being called upon to apply these novel immune and targeted strategies in a patient-centric manner. During this PeerView CME/MOC-certified activity, an expert faculty panel will share the clinical science and current evidence on novel targeted and immunotherapeutic strategies in the upfront and previously treated advanced RCC settings. Upon completion of this activity, participants should be better able to: Summarize the latest efficacy and safety data on new treatment approaches for advanced and/or resectable renal cell carcinoma (RCC), including targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, and novel combination approaches, Select optimal frontline treatment options, such as dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors, for individual patients with advanced RCC based on the latest clinical evidence and relevant patient- and disease-related factors, Apply new clinical trial evidence to the selection and sequencing of novel agents and combination therapies for individual patients with advanced RCC that have progressed after one or more previous lines of therapy, taking into account patient treatment history and comorbidities, Employ effective strategies to proactively mitigate and manage adverse events related to targeted and immune-based therapies for advanced RCC.

1hr 16mins

21 Apr 2021

Episode artwork

Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC

38mins

19 Feb 2020

Episode artwork

Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC

37mins

19 Feb 2020

Episode artwork

Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC

38mins

19 Feb 2020